The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment
can revert or arrest progression of this disease. AD pathology is characterized by the …

Abstract In 2011, the National Institute on Aging and Alzheimer's Association created
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …

Importance There are limited efficacious treatments for Alzheimer disease. Objective To
assess efficacy and adverse events of donanemab, an antibody designed to clear brain …

Background A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ)
peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being …

With the potential development of new disease-modifying Alzheimer's disease (AD)
therapies, simple, widely available screening tests are needed to identify which individuals …

Objective The glymphatic system cleans amyloid and tau proteins from the brain in animal
studies of Alzheimer disease (AD). However, there is no direct evidence showing this in …

Importance Positron emission tomography (PET) imaging now allows in vivo visualization of
both neuropathologic hallmarks of Alzheimer disease (AD): amyloid-β (Aβ) plaques and tau …

Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established
biomarker of Alzheimer's disease (AD), reflecting abnormal tau metabolism in the brain …

Importance β-amyloid plaques and neurofibrillary tau deposits biologically define Alzheimer
disease. Objective To perform post hoc analyses of amyloid reduction after donanemab …

The accumulation of pathological misfolded tau is a feature common to a collective of
neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is …